2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CA125 as a Marker of Heart Failure in the Older Women: A Population-Based Analysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          (1) Background: Cancer antigen 125 (CA125) is a glycoprotein that is expressed by tissue derived from coelomic epithelium in the pleura, peritoneum, pericardium. It has been shown that CA125 concentrations are correlated with NT-proBNP in older people with congestive heart failure (HF). We conducted a study on the association between concentrations of CA125 and NT-proBNP in a population-based cohort of older Polish women. (2) Methods: The current research is sub-study of a large, cross-sectional research project (PolSenior). The study group consisted of 1565 Caucasian women aged 65–102 years. To assess the relationship between CA125 and other variables a stepwise backward multivariate normal and skew-t regression analyses were performed. (3) Results: The median of CA125 concentration was 13.0 U/mL and values over the upper normal range limit (35 U/mL) were observed in 5.1% ( n = 79) of the study cohort. The concentration of CA125 was positively related to age, hospitalization for HF and history of atrial fibrillation and chronic obstructive pulmonary disease, levels of NT-proBNP, IL-6, hs-CRP and triglycerides. We found in the multivariate analyses, that increased CA125 levels were independently associated with log 10 (IL-6) (β = 11.022), history of hospitalization for HF (β = 4.619), log 10 (NT-proBNP) (β = 4.416) and age (β = 3.93 for 10 years). (4) Conclusions: Despite the association between CA125 and NT-proBNP, the usefulness of CA125 for the detection of HF in older women is limited by factors such as inflammatory status and age.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: not found
          • Article: not found

          2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.

            To determine the epidemiology of CA-125 in women without ovarian cancer. We analyzed demographic, medical and lifestyle characteristics related to CA-125, measured using the Centocor CA-125II RIA assay, among 25,608 multi-ethnic U.S. women aged 55-74 years enrolled in a cancer screening trial and found to have no evidence of ovarian cancer. Mean CA-125 level was 11.9 U/ml (SD 8.3); median 10.0 U/ml, interquartile range 8.0-14.0. High levels, using the clinical cut point of >or=35 U/ml, were associated with increased age (p<0.001) and former smoking (p<0.021), while hysterectomy and obesity were protective (p<0.001). Mean levels were higher with increasing age (p<0.001), ever use of hormone therapy (p<0.001), former smoking (p<0.017) and history of breast cancer (p<0.002), but lower (p<0.001) with non-White status, previous hysterectomy, current smoking, and obesity. Current hormone therapy use was not associated with CA-125 in women without a uterus. In post-menopausal women without ovarian cancer, CA-125 level is influenced by a number of factors, including race/ethnicity, age, hysterectomy, smoking history and obesity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Factors influencing serum CA125II levels in healthy postmenopausal women.

              Our objective was to identify factors that correlate with CA125 concentrations in healthy postmenopausal women and to introduce recommendations for reporting and interpreting individual CA125 assay results. We analyzed repeated serum CA125 levels, as measured by the CA125II assay, in 18,748 postmenopausal women who participated in the ST: Bartholomew's/Royal London Hospital Ovarian Cancer screening trial from 1986 to 1994 and were not diagnosed with ovarian cancer during the 12-year follow-up period. We found that race is a substantial predictor of normal levels of CA125, with average CA125II concentration from African (median, 9.0; 95% range, 4.0-26.0 units/ml) and Asian women (median, 13.0; range, 5.9-33.3 units/ml) lower than that in Caucasian women (median, 14.2; range, 6.0-41.0 units/ml; P 0.05). We concluded that clinically significant differences in individual patient characteristics need to be reflected in the screening algorithms that use CA125II so that designed performance characteristics (sensitivity and specificity) are maintained in practice.
                Bookmark

                Author and article information

                Journal
                J Clin Med
                J Clin Med
                jcm
                Journal of Clinical Medicine
                MDPI
                2077-0383
                03 May 2019
                May 2019
                : 8
                : 5
                : 607
                Affiliations
                [1 ]Department of Internal Diseases and Oncological Chemotherapy, School of Medicine in Katowice, Medical University of Silesia, 40-027 Katowice, Poland; chj@ 123456poczta.fm
                [2 ]Department of Statistics, Department of Instrumental Analysis, School of Pharmacy and Laboratory Medicine in Sosnowiec, Medical University of Silesia, 41-200 Sosnowiec, Poland; echelmecka@ 123456sum.edu.pl (E.C.); aowczarek@ 123456paintbox.com.pl (A.J.O.)
                [3 ]First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-635 Katowice, Poland; kmizia@ 123456op.pl
                [4 ]Department of Gynecology and Obstetrics, School of Medicine in Katowice, Medical University of Silesia, 40-752 Katowice, Poland; awitek@ 123456sum.edu.pl
                [5 ]International Institute of Molecular and Cell Biology, Warsaw 02-109, Poland; a.szybalska@ 123456iimcb.gov.pl
                [6 ]Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, 31-531 Cracow, Poland; tomekg@ 123456su.krakow.pl
                [7 ]Health Promotion and Obesity Management Unit, Department of Pathophysiology, School of Medicine in Katowice, Medical University of Silesia, 40-752 Katowice, Poland; magols@ 123456esculap.pl
                [8 ]Pathophysiology Unit, Department of Pathophysiology, School of Medicine in Katowice, Medical University of Silesia, 40-752 Katowice, Poland
                Author notes
                [* ]Correspondence: lek.weronikabulska@ 123456gmail.com ; Tel.: +48-322-526-091
                Author information
                https://orcid.org/0000-0002-0111-438X
                https://orcid.org/0000-0002-6367-7794
                Article
                jcm-08-00607
                10.3390/jcm8050607
                6572540
                31058877
                50a98a47-9e52-4546-b01c-11030a7518c7
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 17 February 2019
                : 30 April 2019
                Categories
                Article

                carbohydrate antigen-125,heart failure,inflammatory marker,older women

                Comments

                Comment on this article